Tumor hypoxia (Figure 5, A and E) and CD45+ cell infiltrates (Figure 5, A and F) were also reduced in SHP2-silenced tumors compared with p-LKO tumors on day 9, but the proportion of Ki67+ tumor cells was increased in SHP2-silenced tumors compared with that in p-LKO tumors (Figure 5, A and G). The gene discussed is PTPRC; the disease is neoplasm.